Ultra-pure Continuous-release Melatonin

David C. Brodner, M.D. performed a two-year study to evaluate the safety profile of the only ultra-pure continuous-release melatonin available on the market — REMfresh. The data has been published in a supplement to the journal SLEEP and will be presented in August at Virtual SLEEP 2020. The REMfresh Safety Update at 24 Months (REMSU24) study captured and analyzed serious and non-serious adverse event reports for REMfresh over a 24-month period from March 9, 2017 to March 9, 2019. Dr. Brodner found only 51 non-serious side-effects out of the 320,000 people who used REMfresh to manage their insomnia.

Read more





Schedule Your Appointment

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

* All indicated fields must be completed.
Please include non-medical questions and correspondence only.

Office Hours

Mon - Fri: 8AM - 4:30PM
Sat & Sun: Closed

Accessibility Toolbar